Julie C. Price
YOU?
Author Swipe
View article: Regional tau burden emerges following beta‐amyloid chronicity timeline in the Down syndrome population
Regional tau burden emerges following beta‐amyloid chronicity timeline in the Down syndrome population Open
Background Previous work in the Down syndrome (DS) population has revealed early and accelerated accumulation of Alzheimer’s disease (AD) pathology when compared with neurotypical adults. Temporal models of [ 11 C]PiB PET beta‐amyloid (Aβ)…
View article: Biomarker and cognitive associates of resistance to neocortical tau pathology in a pooled cohort
Biomarker and cognitive associates of resistance to neocortical tau pathology in a pooled cohort Open
Background Prior evidence suggests that neocortical tau in those with higher β‐amyloid (Aβ) may be the main driver of Alzheimer's disease (AD)‐related neurodegeneration leading to insidious cognitive decline and ultimately a diagnosis of A…
View article: Correcting [ <sup>18</sup> F]MK‐6240 <i>SUVR</i> for non‐equilibrium effects using tissue clearance correction method does not improve its performance
Correcting [ <sup>18</sup> F]MK‐6240 <i>SUVR</i> for non‐equilibrium effects using tissue clearance correction method does not improve its performance Open
Background Honhar et al. (PMCID:10993874) reported a method for bias and noise correction in standardized‐uptake value ratios ( SUVR , simplified outcome), relative to distribution volume ratios ( DVR , quantitative gold‐standard), without…
View article: The remote Mobile Toolbox for capturing cognitive change in preclinical Alzheimer’s disease
The remote Mobile Toolbox for capturing cognitive change in preclinical Alzheimer’s disease Open
Background Remote, smartphone‐based cognitive assessments such as the Mobile Toolbox (MTB) may facilitate the accessibility and scalability of Alzheimer’s disease (AD) research and clinical trials. We previously showed that a composite of …
View article: Preliminary autopsy findings from the Harvard Aging Brain Study
Preliminary autopsy findings from the Harvard Aging Brain Study Open
Background The Harvard Aging Brain Study (HABS) is a longitudinal observational study on the differences between “normal” aging and preclinical AD. Sixteen HABS participants have undergone brain donation. We evaluate to what extent PET bio…
View article: Biomarker and cognitive associates of resistance to neocortical tau pathology in a pooled cohort
Biomarker and cognitive associates of resistance to neocortical tau pathology in a pooled cohort Open
Background Prior evidence suggests that neocortical tau in those with higher β‐amyloid (Aβ) may be the main driver of Alzheimer’s disease (AD)‐related neurodegeneration leading to insidious cognitive decline and ultimately a diagnosis of A…
View article: Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts
Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts Open
Background In late‐onset AD, β‐amyloid (Aβ) deposition is associated with limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC), beginning in the amygdala and spreading to the hippocampus and neocortex. The …
View article: Baseline amyloid spatial extent in combination with tau burden captures cognitive decline, measured digital clock drawing test and PACC5, in preclinical Alzheimer's disease
Baseline amyloid spatial extent in combination with tau burden captures cognitive decline, measured digital clock drawing test and PACC5, in preclinical Alzheimer's disease Open
Background Digital cognitive assessments have potential to improve detection of early cognitive changes in emerging Alzheimer's disease (AD) pathology in preclinical AD. Spatial extent (EXT) measures the spread of amyloid‐b (Ab) and is pot…
View article: Quantifying extracerebral off‐target contamination in [ <sup>18</sup> F]MK6240 PET imaging using compartmental modeling
Quantifying extracerebral off‐target contamination in [ <sup>18</sup> F]MK6240 PET imaging using compartmental modeling Open
Background [ 18 F]MK6240 exhibits high affinity to Alzheimer's disease (AD) tauopathy, but meningeal or extracerebral off‐target signal (Figure 1AB) complicates early tau detection. We previously demonstrated that [ 18 F]MK6240 off‐target …
View article: Preliminary autopsy findings from the Harvard Aging Brain Study
Preliminary autopsy findings from the Harvard Aging Brain Study Open
Background The Harvard Aging Brain Study (HABS) is a longitudinal observational study on the differences between “normal” aging and preclinical AD. Sixteen HABS participants have undergone brain donation. We evaluate to what extent PET bio…
View article: Higher Amyloid and Tau Burden Is Associated With Faster Decline on a Digital Cognitive Test
Higher Amyloid and Tau Burden Is Associated With Faster Decline on a Digital Cognitive Test Open
Objective A 2‐min digital clock‐drawing test (DCTclock) captures more granular features of the clock‐drawing process than the pencil‐and‐paper clock‐drawing test, revealing more subtle deficits at the preclinical stage of Alzheimer's disea…
View article: Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies Open
Following regulatory approval of anti‐amyloid beta (Aβ) therapies, a better characterization of patients receiving these treatments is needed to guide clinical management and inclusion in future trials. This Alzheimer's Association‐convene…
View article: Simultaneous EEG-PET-MRI identifies temporally coupled and spatially structured brain dynamics across wakefulness and NREM sleep
Simultaneous EEG-PET-MRI identifies temporally coupled and spatially structured brain dynamics across wakefulness and NREM sleep Open
Sleep entails significant changes in cerebral hemodynamics and metabolism. Yet, the way these processes evolve throughout wakefulness and sleep and their spatiotemporal dependence remain largely unknown. Here, by integrating a functional P…
View article: Tangible advantages of multi-stage brain motion compensation for PET imaging demonstrated in multiple studies
Tangible advantages of multi-stage brain motion compensation for PET imaging demonstrated in multiple studies Open
Head motion is a persistent challenge in positron emission tomography (PET) brain imaging, reducing quantitative accuracy, degrading time-activity curves (TACs), and complicating kinetic modeling. We evaluated a fully automated, multi-stag…
View article: Estimating the preclinical Alzheimer's disease course with multimodal data
Estimating the preclinical Alzheimer's disease course with multimodal data Open
INTRODUCTION In observational studies of preclinical AD, an arbitrary “baseline” can obscure where an individual is located along a theoretical continuum. Optimizing longitudinal trajectories can distill multiple, non‐linearly distributed …
View article: Preliminary Investigation of Obstructive Sleep Apnea and Alzheimer’s Disease in Down Syndrome
Preliminary Investigation of Obstructive Sleep Apnea and Alzheimer’s Disease in Down Syndrome Open
This study provided a preliminary examination of indices of obstructive sleep apnea (OSA) and sleep disruptions in adults with Down syndrome (DS), and their associations with Alzheimer’s disease (AD) pathology and symptomatology. Ninety-th…
View article: The Mobile Toolbox for remote, self‐administered cognitive assessment in older adults: associations with in‐clinic cognitive testing and Alzheimer's disease biomarkers
The Mobile Toolbox for remote, self‐administered cognitive assessment in older adults: associations with in‐clinic cognitive testing and Alzheimer's disease biomarkers Open
INTRODUCTION Remote, smartphone‐based cognitive assessments such as the Mobile Toolbox (MTB) may increase the accessibility of Alzheimer's disease (AD) clinical trials. We examined the feasibility of the MTB among cognitively unimpaired (C…
View article: Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross‐sectional associations with early cognitive impairments
Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross‐sectional associations with early cognitive impairments Open
INTRODUCTION Individuals with Down syndrome (DS) have elevated risks for Alzheimer's disease (AD) due to amyloid beta (Aβ) precursor protein overexpression, with nearly all developing AD pathology by age 40 at autopsy. This study examined …
View article: Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome
Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome Open
INTRODUCTION Weight loss has been linked to early Alzheimer's disease (AD) pathology, possibly through metabolic dysregulation. We examined changes in body mass index (BMI) in relation to AD biomarkers (amyloid beta [Aβ] and tau) and cogni…
View article: Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome
Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome Open
INTRODUCTION Gait abnormalities are associated with Alzheimer's disease (AD) in the general population, but it is unclear if the same is true for individuals with Down syndrome (DS). This study examined gait across 32 months in relation to…
View article: The striatum is an early, accurate indicator of amyloid burden using [ <sup>11</sup> C]PiB in Down syndrome: Comparison of two radiotracers
The striatum is an early, accurate indicator of amyloid burden using [ <sup>11</sup> C]PiB in Down syndrome: Comparison of two radiotracers Open
INTRODUCTION Adults with Down syndrome demonstrate striatum‐first amyloid accumulation with [ 11 C]Pittsburgh Compound‐B (PiB) positron emission tomography (PET) imaging, which has not been replicated with [ 18 F]florbetapir (FBP). Early s…
View article: A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials
A head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials Open
Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. A barrier to recruitment for anti-amyloid trials includes the availability of the same am…
View article: Correlating hippocampal and amygdala volumes with neuropathological burden in Down syndrome and Alzheimer’s disease and related neurodegenerative pathologies using 7T postmortem MRI
Correlating hippocampal and amygdala volumes with neuropathological burden in Down syndrome and Alzheimer’s disease and related neurodegenerative pathologies using 7T postmortem MRI Open
Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC), is common in elderly brains and often seen in conjunction with Alzheimer’s disease neuropathologic change (ADNC). LATE-NC typically begins in the amygda…
View article: Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer’s disease
Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer’s disease Open
Elucidating the downstream impact of exogenous hormones on the aging brain will have far-reaching consequences for understanding why Alzheimer’s disease (AD) predominates in women almost twofold over men. We tested the extent to which meno…
View article: [<sup>18</sup>F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [<sup>15</sup>O]Water
[<sup>18</sup>F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [<sup>15</sup>O]Water Open
[18F]MK-6240 PET (where MK-6240 is 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is used to assess in vivo tau deposition across the Alzheimer disease (AD) spectrum. We aimed to quantify the associations and bias of earl…
View article: Rethinking the residual approach: leveraging statistical learning to operationalize cognitive resilience in Alzheimer’s disease
Rethinking the residual approach: leveraging statistical learning to operationalize cognitive resilience in Alzheimer’s disease Open
Cognitive resilience (CR) describes the phenomenon of individuals evading cognitive decline despite prominent Alzheimer's disease neuropathology. Operationalization and measurement of this latent construct is non-trivial as it cannot be di…
View article: Simultaneous EEG-PET-MRI identifies temporally coupled, spatially structured hemodynamic and metabolic dynamics across wakefulness and NREM sleep
Simultaneous EEG-PET-MRI identifies temporally coupled, spatially structured hemodynamic and metabolic dynamics across wakefulness and NREM sleep Open
Sleep entails significant changes in cerebral hemodynamics and metabolism. Yet, the way these processes evolve throughout wakefulness and sleep and their spatiotemporal dependence remain largely unknown. Here, by integrating a novel functi…
View article: Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup Open
The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau…
View article: A comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials
A comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials Open
Adults with Down syndrome carry high risk of developing Alzheimer’s disease and efforts to include this population in clinical trials remain limited. A barrier to recruitment for anti-amyloid trials includes the availability of the same am…
View article: Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup Open
INTRODUCTION The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develo…